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Abstract 
Terpenoids are an exceptionally large family of natural products, and contain 
numerous bioactive members that are pharmaceutically important. While most research 
into terpenoids and their metabolism has thus far occurred in non-fungal organisms, 
chiefly plants, Basidiomycota (mushroom forming fungi) are well known as prolific 
producers of bioactive sesquiterpenoids, such as the potent anticancer compounds Illudin 
M and S. While natural products have traditional been a huge driver of pharmaceutical 
discovery, this natural abundance is often hampered by very low expression in the native 
host and slow growth or rarity of the host itself. This drives up financial and 
environmental costs, and in many cases makes the production of otherwise useful natural 
products impracticable.  
One potential solution to this quandary is heterologous production of secondary 
metabolites in non-native hosts such as Escherichia coli and Saccharomyces cerevisiae. 
Another avenue is in vitro biocatalysis, wherein the biosynthetic enzymes of the native 
host are heterologously expressed, isolated, and used to perform synthesis outside of the 
cell. This approach avoids the fragility of the in vivo system and would allow the creation 
of combinatorial enzymatic pathways to create novel bioactive structures. With regards to 
constructing a sesquiterpenoid biosynthetic pathway, many stable terpene synthases have 
been isolated and shown to be active in vitro. However, the most well studied terpene 
scaffold modifying enzymes, cytochrome P450s, are notoriously difficult to 
heterologously express in active form. In order to obtain scaffold modifying oxygenases 
capable of being part of an in vitro terpenoid biosynthetic pathway, fungal oxygenases 
aside from cytochrome P450s were investigated. Specifically, unspecific peroxygenase 
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from Agrocybe aegerita and flavin binding oxidoreductases from Δ6-protoilludene 
biosynthetic gene clusters were expressed and assayed against the sesquiterpene scaffold.  
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Chapter 1: Introduction 
 For millennia, humans have used plants and fungi as our primary source of salves 
and medicines. The bioactive chemical compounds of these organisms are termed natural 
products, also known as secondary metabolites. Unlike primary metabolites, which are 
essential for an organism’s life and ability to function, secondary metabolites are not 
required for survival. Many secondary metabolites are chemical warfare agents which 
confer an evolutionary advantage against competitors, pathogens, and predators, and have 
cytotoxic properties which can be applied against bacteria, fungi, and cancer cells.1 In 
more recent times, natural products became the basis for the majority of modern 
medicines. Aspirin, derived from salicylic acid isolated from willow bark,2  morphine 
from opium poppy, quinine from Cinchona succirubra,1 and penicillin from the mold 
Penicillium notatum, 3 are only some of a multitude of modern pharmaceuticals derived 
or isolated from natural sources. In the past 30 years, 61% of approved anticancer 
compounds and 49% of approved anti-infectives were derived from or inspired by natural 
products. 4 
Terpenoids, which are formed from five-carbon isoprenyl diphosphate 
molecules,5 are considered to be the largest and most diverse class of natural products.6 
This class contains many pharmaceutically important compounds such as artemisinin (the 
basis of numerous anti-malarial drugs), paclitaxel (chemotherapy medication) and 
pleuromutilin (the source of the anti-biotic semi-synthetic derivatives tiamulin, 
valnemulin, and retapamulin).7 Traditionally, terpenoids and other natural products are 
isolated by extraction from native host material. However, this harvesting method has 
significant drawbacks, chiefly that the supply of host material is often limited and 
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extraction yields are often very low.8 This increases drug price and can also lead to 
environmental degradation. An example of this is the terpenoid paclitaxel, a very 
important anti-cancer drug, which was initially harvested from the bark of the Pacific 
Yew (Taxus brevifolia). Paclitaxel exists in low concentrations (0.01% - 0.05%) in the 
bark of T. brevifolia. In order to extract 1 kg of paclitaxel (capable of treating five 
hundred patients), up to 300 T. brevifolia trees must be killed to provide 10 tons of bark. 
As T. brevifolia grows slowly and is relatively uncommon, the strategy of direct 
extraction from bark is unsustainable both financially and ecologically.9  
While total chemical synthesis of natural products is feasible for simpler 
molecules such as aspirin,2  many natural products and especially terpenoids such as 
paclitaxel are very complex, making total synthesis impractical due to loss of yield over 
many steps and the production of inactive or toxic isomers.8,10 If extraction from the 
native source material and total chemical synthesis have many drawbacks, a potentially 
viable alternate method is production of the target molecule in a heterologous host. This 
can be done in vivo by using recombinant DNA technology to express the enzymes of the 
natural product pathway in the heterologous host, which is typically S. cerevisae or E. 
coli as these organisms have been well characterized. Heterologous production of the 
artemisinin precursor artemisinic acid was achieved through the recombinant introduction 
of the nine genes of the mevalonate pathway, expression of the Artemisia annua 
amorphadiene synthase, a cytochrome P450 and its reductase, another cytochrome 
enzyme, and two dehydrogenases in S. cerevisiae. This resulted in the production of 25 
g/L of artemisinic acid, which is extracted and modified by organic synthesis to 
artemisinin, a process currently undergoing large scale industrial implementation.2  
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In addition to in vivo production of natural products, these molecules can also be 
biosynthesized in vitro by heterologously expressing, purifying, and isolating the 
requisite enzymes and performing the reactions in an otherwise artificial system. Some 
benefits of the in vitro approach include the ability to use substrates and produce products 
that may be toxic to an in vivo host, and the possibility of utilizing reaction media that is 
incompatible with an in vivo system (such as organic solvents). In vitro biocatalysis also 
allows the order of enzymatic reactions to be easily rearranged, and non-native enzymes 
can be used to further modify the natural product, or enzymes from different pathways 
can be utilized in tandem to create molecules with novel structures and bioactivities. 
However, in vitro biocatalysis is challenged by the difficulty of isolating enzymes that are 
active and stable in vitro, and the need to externally supply expensive co-factors.8  
Heterologous production of terpenoids, in vivo or in vitro, could produce a much 
needed boost to pharmaceutical research and production. One important but relatively 
untapped source of terpenoid natural products is Basidiomycota, or mushroom forming 
fungi.11 Basidiomycota have played a crucial role in traditional medicine since ancient 
times, they are known to produce a great range of natural products with antibacterial, 
anti-cancer, and anti-fungal activity, and terpenoids are one of the most common classes 
they produce. 5,11,12,13 Most investigation into fungal terpenoid metabolism has focused on 
Ascomycota (filamentous fungi), with relatively little research into the metabolism of 
Basidiomycota natural products. This is likely due to the fact that Ascomycota are easy to 
grow in a laboratory and are genetically tractable, while Basidiomycota are difficult or 
impossible to grow in the laboratory and with a few exceptions are not genetically 
tractable. However, with advances in fungal genome sequencing and synthetic biology, 
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elucidation of Basidiomycota natural product metabolism is becoming more and more 
feasible.5  
If heterologous production of basidiomycete terpenoids is to be achieved, their 
metabolic pathways must first be characterized and then transferred to the production 
host. While specific enzymes may still need to be identified, the general outline of 
terpenoid biosynthesis is known: (I): synthesis of isoprenyl diphosphate precursors, (II), 
cyclization of the precursor molecule into the hydrocarbon terpene backbone, (III) 
scaffold modification. In fungi the five carbon precursor isopentenyl diphosphate (IPP) is 
synthesized from acetyl-CoA through the mevalonate pathway, and a portion of the IPP 
produced is isomerized to dimethylallyl pyrophosphate (DMAPP) by IPP isomerase.5,14 
An alternative route to IPP and DMAPP, known as the 1-deoxy-D-xylulose 5-phosphate 
(DXP) pathway, is used by E. coli and some other bacteria, while plants utilize both 
pathways.2 IPP units are sequentially added to DMAPP in a 1’-4 condensation reaction 
catalyzed by isoprenyl diphosphate synthase, resulting in geranyl pyrophosphate (GPP), 
farnesyl pyrophosphate (FPP), or geranylgeranyl pyrophosphate (GGPP), which contain 
10, 15, and 20 carbons respectively.5 
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Figure 1.1 - Biosynthesis of isoprenyl diphosphate terpenoid precursors  
These precursors are dephosphorylated by terpene synthases (also known as 
terpene cyclases), and undergo an ionization dependent (Class I) or protonation 
dependent (Class II) cyclization cascade and yield the hydrocarbon (10 carbon) mono-, 
(15 carbon) sesqui-, (20 carbon) di-, or (30 carbon) triterpene scaffolds.5,13 The terpene 
scaffolds are then acted upon by scaffold modifying enzymes such as cytochrome P450 
dependent monooxygenases (CYPs), oxidoreductases and transferases.13 Basidiomycota 
are most well known for producing biologically active sesquiterpenoids,7 which contain 
15 carbons and are synthesized from farnesyl pyrophosphate, typically by Class I terpene 
synthases. The sesquiterpene synthase mediates metal ion induced departure of 
pyrophosphate from FPP, resulting in a highly reactive farnesyl carbocation that 
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undergoes ring closure at the 1,6, 1,10, or 1,11 position  followed by further cyclization 
reactions and ring rearrangements which form the sesquiterpene scaffold.13  
While Basidiomycota do produce a number of sesquiterpenes derived from 1,6 
and 1,10 cyclized cations, most of the medically relevant basidiomycete sesquiterpenoids 
are derived from the 1,11 cyclized trans-humulyl cation. Sesquiterpenoid classes derived 
from this cation include the caryophyllanes, africananes, tremulanes, humulanes, 
sterpuranes, hirsutanes, pentalenene derivatives, and Δ6-protoilludene derivatives (see 
Figure 2 below).1
 
Figure 1.2 - Different classes of terpenoid scaffolds derived from the 1,11 
cyclized trans-humulyl cation. 
The Δ6-protoilludene scaffold in particular is the precursor for a variety of 
bioactive terpenoids, such as the illudanes, marasmanes, lactaranes, and fommanosanes 
(see Figure 1.3 below). Two of the most promising pharmaceutical candidates from 
 7   
 
Basidiomycota, the Omphalatus olearius illudanes known as Illudin M and S, are 
currently being developed as anti-cancer therapeutics.13  
 
Figure 1.3 - Different bioactive terpenoid classes derived from the Δ6-
protoilludene scaffold.   
Achieving heterologous biosynthesis of fungal terpenoids would enable medical 
investigation of many bioactive compounds that have been isolated but are only produced 
in minute quantities, and in the case of prospective pharmaceuticals such as Illudin M and 
S could provide the ability to produce future drugs on an industrial scale. If fungal 
terpenoid biosynthesis could be achieved in vitro, it would circumvent the inherent 
fragility of living systems that can complicate in vivo biosynthesis. In addition, with an in 
vitro biosynthesis pathway the biocatalytic enzymes could be rearranged, utilized in 
another pathway, or new enzymes could be added to the pathway to generate a variety of 
novel molecules with potential bioactivities. In this thesis, I will give a description of my 
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attempts to create a combinatorial, enzymatic pathway for the in vitro biocatalysis of 
fungal sesquiterpenoids.  
 The sesquiterpene precursor FPP is commercially available and can be added 
directly to the biocatalytic reaction mixture. In order to achieve an enzymatic cascade, 
sesquiterpene synthases and scaffold modifying enzymes that are active and stable in 
vitro are required. A number of fungal sesquiterpene synthases have been heterologously 
expressed and shown to be both stable and active in vitro. The Schmidt-Dannert lab has 
previously expressed and isolated a wide variety of sesquiterpene synthases from the 
mushrooms Coprinus cinereus,15 Omphalotus olearius16 and Stereum hirsutum17 
including a number of Δ6-protoilludene synthases which are available for use in the lab. 
A number of these sesquiterpene synthases, such as the α-cuprenene synthase Cop6 from 
C. cinereus, the Δ6-protoilludene synthases Omp6 and Omp7 from O. olearius, and the 
prototilludene synthases Stehi1|25180, Stehi1|64702 and Stehi1|73029, from S. hirsutum 
are located in large biosynthetic gene clusters containing a number of scaffold modifying 
enzymes.15,16,17 
CYPs are the most common scaffold modifying enzyme in sesquiterpenoid 
biosynthesis,7 and indeed the sesquiterpene synthase gene clusters from C. cinereus, O. 
olearius, and S. hirsutum contain a number of CYP genes.15,16,17 However, the use of 
fungal CYPs in heterologous enzymatic pathways is complicated by the difficulty of 
expressing active CYPs. Most eukaryotic CYPs are membrane bound18 and when 
expressed in heterologous hosts these enzymes often suffer from low expression levels, 
instability, protein misfolding, and aggregation into inclusion bodies. Thus in 
heterologous expression, it is common for fungal CYPs to not express at all or express in 
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inactive form.58 While two  C. cinereus cytochrome P450 enzymes (Cox1 and Cox2) in 
the biosynthetic cluster of Cop6 appeared to have activity on α-cuprenene when 
coexpressed with Cop6,15 other attempts to heterologously express CYPs from the 
sesquiterpenoid biosynthetic gene clusters of C. cinereus, O. olearius, and S. hirsutum 
have not yielded activity (unpublished data).  
As Δ6-protoilludene is the precursor to many of the most bioactive fungal 
sesquiterpenoids, I focused my efforts on creating a biosynthetic pathway to Δ6-
protoilludene derivatives. In addition to the potential pharmaceutical benefits of 
synthesizing Δ6-protoilludene derivatives, it would also be interesting to discover an 
enzyme which causes the opening and rearrangement of Δ6-protoilludene’s strained 
cyclobutane ring. This is a crucial yet mysterious step that results in much of the 
structural diversity of Δ6-protoilludene derivatives. Δ6-protoilludene is easily supplied in 
vitro by the activity of the Stehi7 Δ6-protoilludene synthase from S. hirsutum.. To 
produce the final terpenoid product, it is necessary to assemble an ensemble of scaffold 
modifying enzymes with different activities. As CYP enzymes have proven to be difficult 
to express in active form, alternate fungal scaffold modifying enzymes were 
heterologously expressed and investigated for activity against sesquiterpenes. The 
remainder of this thesis describes an investigation of the activity of A) a mutant of the 
unspecific peroxygenase UPO from the mushroom Agrocybe aegerita, which was 
evolved by another lab group for expression in S. cerevisiae19 and B) flavin-binding 
enzymes found in the biosynthetic gene clusters of the O. olearius Omp7 Δ6-
protoilludene synthase and the S. hirsutum Stehi7 Δ6-protoilludene synthase.  
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Chapter 2 
Expression and investigation of AaeUPO mutant PaDa I 
Introduction 
 A. aegerita unspecific peroxygenase (UPO) is a mono-peroxygenase that I 
investigated for activity against the ∆6-protoilludene sesquiterpene scaffold. Broadly, 
peroxygenases are enzymes that transfer a peroxide borne oxygen atom to substrates.20 
UPO was first isolated from Agrocybe aegerita, a popular edible basidiomycete which 
grows on wood and bark mulch and is found throughout the Mediterranean region.21 
Interest in UPO increased greatly as it was shown to be capable of oxygenating linear, 
branched and cyclic alkenes and alkanes (with alkanes ranging in size from propane (C3) 
to hexadecane (C16)),
22,23 aromatic compounds such as naphthalene,24 and benzene,25 
heterocycles such as dibenzofuran,26 and ethers (causing cleavage)27 among other 
substrates. UPOs are capable of performing dealkylation, hydroxylation, epoxidation, 
aromatization, sulfoxidation, dechlorination, and halide oxidation.20 The selective 
oxygenation of poorly activated C – H bonds is considered a “dream reaction” in organic 
chemistry, as it is difficult to accomplish and very desired within industrial and 
pharmaceutical synthesis.28 The other principal group of enzymes capable of 
functionalizing C – H bonds are cytochrome P450s, which have been well studied. Often, 
the products of unspecific peroxygenase reactions are similar to human cytochrome 
P450s.20 However, unlike CYPs which are membrane bound, fragile, and co-factor 
dependent, UPOs are soluble, excreted extracellularly, stable, and only require low (1-2 
mM) amounts of H2O2 in order to be active.
19,29  In addition, use of UPO can enable 
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increased (when compared with traditional metal catalysts) or near complete 
stereoselectivity or regioselectivity.23,30  
 UPOs are one of two types of enzymes which are part of the heme thiolate 
peroxidase superfamily, the other enzyme type being the chloroperoxidase.31 
Chloroperoxidase is secreted by the filamentous fungus Caldariomyces fumago, and 
catalyzes oxidative chlorination,32 as well as epoxidation of linear alkenes and 
hydroxylation of benzylic carbons. However, it is unable to oxygenate stronger C – H 
bonds such as those found in aromatic compounds or alkanes.20 Heme thiolate 
peroxidases all contain a heme domain in the active site, and a thiolate group which acts 
as a ligand to the heme FeIII ion.19  
 After the discovery of A. aegerita UPO (AaeUPO), other UPOs were also isolated 
from the fungi Coprinus radians (CraUPO)33 and Marasmius rotula (MroUPO).34 In 
addition, it is known that at least eight other mushrooms secrete UPOs. When genetic 
databases are searched for UPO like sequences, approximately 2000 putative UPO 
sequences are found in fungi.20 These UPOs can be divided into two groups based on 
their length: short UPOs are on average 29 kDa and contain CPO and MroUPO, while 
long UPOs are on average 44 kDa and contain AaeUPO and CraUPO.20 
UPOs transfer oxygen to substrates in a similar manner as CYPs (the “peroxide 
shunt” pathway), and also oxidize substrates in a similar manner as heme peroxidases. In 
this way, UPOs potentially represent an evolutionary “missing link” between the CYP 
and heme peroxidase enzyme classes20 (see Figure 4 below). In the UPO oxidation 
mechanism, an oxoiron(IV) protoporphyrin radical cation intermediate is the species that 
reacts with the substrate.35,36 
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Balanced equation for UPO reaction:20 R-H + H2O2 ⇌ R-OH + H2O 
 
Figure 2.1 – UPO reaction mechanism. Oxidation reaction mechanism for 
unspecific peroxygenase, oxygen transfer reaction shown on left and oxidation 
without oxygen transfer shown on right (taken from Hofrichter et al., 2015).20 
UPOs including AaeUPO were originally harvested directly from fungal culture. 
In order to produce AaeUPO in a manner more amenable to industrial adoption, and in 
order to enable expression of AaeUPO in a system that would allow the creation of 
mutant AaeUPO, Molina-Espeja et al., used directed evolution to optimize AaeUPO for 
secretion in S. cerevisiae.19 Mutagenic PCR was used over five generations to produce a 
mutant AaeUPO (termed PaDa I), with four mutations in the signal peptide and five in 
the body of the enzyme. This process resulted in an increase of UPO expression by 1,114 
fold and a specific activity increase of 3.6 fold, and a total secretion level of 7.8 mg/L. 
Glycosylation increased from 22% for the wild type to 30% for the PaDa I mutant, and 
the mutant was both active and highly stable in the presence of organic cosolvents.19 The 
heavy glycosylation increases UPOs stability, which is one reason it was expressed in 
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yeast (which can glycosylate proteins, while E. coli cannot).  Peroxygenase activity was 
measured by assaying the PaDa I – UPO mutant against 5-nitro-1,3-benzodioxole (NBD), 
transforming NBD into yellow colored 4-nitrocatechol, the increase of which can be 
measured spectrophotometrically at 425 nm.37 Peroxidase activity was measured by 
assaying PaDa I – UPO against 2,2’-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid 
(ABTS), which forms a stable green radical form of ABTS whose formation can be 
measured spectrophotometrically at 418 nm.38 Due to the higher sensitivity of the ABTS 
assay and the fact that peroxidase and monooxygenase activities of PaDa I-UPO are 
closely linked, Molina-Espeja et al. used ABTS activity to measure total enzyme 
activity.19 As AaeUPO is capable of oxyfunctionalizing a wide variety of hydrocarbons of 
varying sizes, including alkanes and alkenes, I hypothesize it will be able to modify 
sesquiterpene scaffolds such as Δ6-protoilludene. Previously, AaeUPO was shown to 
have activity against the monoterpene limonene, producing epoxylimonene and carveol, 
the same products produced by liver CYPs.23 In order to obtain UPO to perform 
sesquiterpene activity assays with, I synthesized the gene coding for the PaDa I – UPO 
mutant, transferred it to a pESC-ura vector, and expressed it  in S. cerevisiae.  
Materials and Methods 
Cloning of PaDa I – UPO gene into pESC-ura expression vector 
The PaDa I – UPO mutant gene was designed according to the description in the 
original paper19 and synthesized through Invitrogen’s GeneArt® service. The gene was 
PCR amplified from the pMX plasmid it arrived in, and cloned with yeast 
recombinational cloning (utilizing BamHI and HindIII restriction enzymes) into a pESC-
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ura vector (from Stratagene) under the control of the Gal1 (galactose inducible) promoter. 
All primers (see Table 2.2) were ordered from Integrated DNA Techologies, and 
Phusion® polymerase and restriction enzymes were purchased from New England 
Biolabs (NEB). Thermo Fisher Scientific Top10 cells were used for plasmid production 
during cloning. GoGreen® Taq polymerase from Promega was used to screen colonies 
for the presence of desired genes, and sequencing was performed at the University of 
Minnesota Genomics Center. The PaDa I - UPO containing pESC-ura plasmid was 
transformed into a BJ5465 protease deficient yeast strain (purchased from American 
Type Culture Collection, i.e. ATCC) using an in house transformation protocol which is 
described in the Supplemental Materials section.  
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Plasmid name Gene and promoter information Selectable 
marker 
Source 
PMX_PaDa_I Contains PaDa I – UPO gene Kanamycin 
resistance 
Synthesized by 
GeneArt® 
(Invitrogen), PaDa I 
–UPO gene from 
Molina-espeja et al19 
pESC-ura Contains the Gal1 and Gal 10 
promoters 
Ampicillin 
resistance, 
URA3* 
marker 
From Schmidt-
Dannert laboratory 
collection, originally 
from Stratagene 
pESC-ura_PaDa_I Contains PaDa I – UPO gene under 
control of the Gal1 promoter 
Ampicillin 
resistance, 
URA3 
This study 
pESC-ura_PaDaI_A1 Contains PaDa I – UPO gene with 
Kozak sequence A1 (see Table 2.6) 
under control of the Gal1 promoter 
Ampicillin 
resistance, 
URA3 
This study 
pESC-ura_PaDaI_A2 Contains PaDa I – UPO gene with 
Kozak sequence A2 (see Table 2.6) 
under control of the Gal1 promoter 
Ampicillin 
resistance, 
URA3 
This study 
pESC-ura_PaDaI_A3 Contains PaDa I – UPO gene with 
Kozak sequence A3 (see Table 2.6) 
under control of the Gal1 promoter 
Ampicillin 
resistance, 
URA3 
This study 
pESC-ura_PaDaI_A4 Contains PaDa I – UPO gene with 
Kozak sequence A4 (see Table 2.6) 
under control of the Gal1 promoter 
Ampicillin 
resistance, 
URA3 
This study 
pESC-ura_PaDaI_A5 Contains PaDa I – UPO gene with 
Kozak sequence A5 (see Table 2.6) 
under control of the Gal1 promoter 
Ampicillin 
resistance, 
URA3 
This study 
pESC-ura_PaDaI_A6 Contains PaDa I – UPO gene with 
Kozak sequence A6 (see Table 2.6) 
under control of the Gal1 promoter 
Ampicillin 
resistance, 
URA3 
This study 
Strain Description Source 
BJ5465 Protease deficient S. cerevisiae strain ATCC 
Top10 Chemically competent E. coli used for plasmid 
production 
ThermoFisher 
Scientific 
*URA3 allows growth on minimal media without added uracil. 
 
 
 
Table 2.1 – Plasmids and strains used in Chapter 2 
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Primer name 5’ – 3’ Sequence Function 
PaDa I F * TATACCTCTATACTTTAACGTCAA
GGAGAAAAAACCCCG 
Amplifies PaDa I-UPO gene from  
PMX_PaDa_I plasmid, amplicon cut with 
BamHI and HindIII restriction enzymes, 
used to clone PaDa I – UPO into pESC-
ura to produce pESC-ura_PaDa_I 
plasmid.  
PaDa I R GGTTAGAGCGGATCTTAGCTAGC
CGCGGTACCAAGCTTACTCG 
A1 F TGGAATATTTTCCCCTGTTCC Performs site directed mutagenesis on 
pESC-ura_PaDa_I plasmid to produce 
pESC-ura_PaDaI_A1 plasmid. 
A1 R TGGTTGAGTCGTATTACGGATC 
A2 F ATACGACTCAACCATGAAATATT
TTCCCCTGTTC 
Performs site directed mutagenesis on 
pESC-ura_PaDa_I plasmid to produce 
pESC-ura_PaDaI_A2 plasmid. A2 R TACGGATCCGGGGTTTTT 
A3 F ATGTCTTATTTTCCCCTGTTCCCA
AC 
Performs site directed mutagenesis on 
pESC-ura_PaDa_I plasmid to produce 
pESC-ura_PaDaI_A3 plasmid. A3 R TTTTTTGTCGTATTACGGATCCGG 
A4 F AATGAAATATTTTCCCCTGTTCCC Performs site directed mutagenesis on 
pESC-ura_PaDa_I plasmid to produce 
pESC-ura_PaDaI_A4 plasmid. 
A4 R TTTTTGTCGTATTACGGATCCGG 
A5 F GTCTTATTTTCCCCTGTTCCCAAC Performs site directed mutagenesis on 
pESC-ura_PaDa_I plasmid to produce 
pESC-ura_PaDaI_A5 plasmid. 
A5 R ATTATTGAGTCGTATTACGGATC 
A6 F ATACGACTCAATAATGAAATATT
TTCCC 
Performs site directed mutagenesis on 
pESC-ura_PaDa_I plasmid to produce 
pESC-ura_PaDaI_A6 plasmid. A6 R TACGGATCCGGGGTTTTT 
* = F indicates forward primer, R indicates reverse primer 
 S. cerevisiae media  
Filter sterilized minimal media for yeast expression contained 6.7 g of yeast 
nitrogen base, 1.92 g of yeast synthetic drop-out medium supplement without uracil, 20 g 
raffinose, 100 μg/mL ampicillin, and ddH2O to 1 L. Selective yeast plates contained 6.7 g 
of yeast nitrogen base, 1.92 g of yeast synthetic drop out medium supplement without 
uracil, 20 g autoclaved bacto agar, 20 g glucose, 100 μg/mL ampicillin and ddH2O to 
1,000 mL. Sterile expression media contained 11 g of yeast extract and 22 g peptone in 
720 mL ddH2O, autoclaved separately as “YP media,”  67 mL 1 M filtered KH2PO4 pH 
Table 2.2 – Primers used in Chapter 2 
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6.0 buffer, 111 mL 20% filtered galactose, 22 mL filtered MgSO4 0.1 M, 31.6 mL 
absolute ethanol, 100 μg/mL ampicillin, and ddH2O to 1,000 mL.  
Expression of PaDa I – UPO in S. cerevisiae 
The yeast expression procedure was adapted from that described in the original 
paper that produced PaDa I – UPO.19 A yeast colony expressing PaDa I – UPO or a 
mutant was picked from a selective plate and used to inoculate 20 mL minimal media 
cultures in 125 mL flasks. These cultures were incubated for 48 h at 30ºC and 220 RPM, 
and then used to inoculate a second set of 20 mL minimal media cultures at a starting 
OD600 of 0.2. Cells were grown for two doubling times (approximately 6-8 hours) and 
then 45 mL of sterile expression media was inoculated with 5 mL of culture. Expression 
cultures were grown for 72 h at 25ºC and 220 RPM (unless otherwise noted), and then 
harvested by centrifugation at 4,500 RPM and 4ºC for 10 minutes. The PaDa I – UPO 
containing supernatant was filter sterilized with a 0.2 micron filter. The protein 
expression level was determined by SDS-PAGE analysis, with overnight staining in 
Coomassie Biosafe® stain. PaDa I – UPO supernatant was occasionally concentrated by 
centrifugation using a Millipore Amicon® Ultra centrifugal filter with a 10,000 Da 
molecular weight cut off limit.  
PaDa I – UPO activity assay 
PaDa I – UPO’s peroxygenase activity was measured by assaying against NBD 
(5-nitro-1,3-benzodioxole),37 while its peroxidase activity was measured by an ABTS 
(2,2’-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) assay.38 The ABTS and NBD 
reaction mixtures were prepared, 10 μL of PaDa I – UPO supernatant was placed in a 
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plastic cuvette, the reaction mixture was added, and spectrophotometric measurements 
were recorded at 418 nm (ABTS) or 425 nm (NBD) every 30 seconds for 2 minutes. 
ABTS reaction mixture contained 100 mM sodium phosphate/citrate buffer at pH 4.4, 0.3 
mM ABTS and 2 mM H2O2, while NBD reaction mixture contained 100 mM potassium 
phosphate buffer pH 7.0, 1 mM NBD, 15% acetonitrile and 1 mM H2O2. Total activity of 
the supernatant was measured using ABTS activity, which was defined as the amount of 
enzyme that oxidizes 1 μmol of ABTS per min in 100 mM sodium phosphate/citrate 
buffer pH 4.4 containing 2 mM H2O2. This was calculated from the average ΔOD418/min 
of three measurements in the ABTS assay, according to the Beer Lambert law and the 
extinction coefficient of ABTS radical cation, which is 36,000 M-1cm-1.  
Purification of PaDa I – UPO  
In order to concentrate and partially purify PaDa I – UPO, the PaDa I – UPO 
supernatant was precipitated with ammonium sulfate. Amount of supernatant and 
ammonium sulfate used in each precipitation is indicated in the Results and Discussion 
section.  Two precipitations were performed, an initial precipitation with a lower 
concentration of ammonium sulfate, after which the precipitate was discarded, and a final 
precipitation, after which the precipitate was kept and the supernatant was discarded. The 
precipitated PaDa I – UPO was resuspended in 10 mM sodium phosphate/citrate pH 4.3 
buffer (buffer A), and either dialyzed or run through a PD 10 desalting column from 
Amersham Biosciences (according to the manufacturers protocol) to remove ammonium 
sulfate in preparation for cation exchange chromatography. The desalted PaDa I – UPO 
solution was filtered and loaded on to a strong cation-exchange column (5 mL HiTrap SP 
HP) pre-equilibrated with buffer A. The proteins were eluted with a gradient of 0 to 25 % 
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1 M NaCl, at a flow rate of 1 mL per minute, over 55 minutes, and then with a gradient of 
25% to 100% NaCl at 1mL/minute over 5 minutes. 
Alteration of Kozak sequences 
Kozak sequences were altered by site directed mutagenesis with the Q5® kit from 
NEB (New England Biolabs). All primers were designed with the NEB software 
NEBaseChanger®, and ordered from Integrated DNA Techologies. Top10® E. coli cells 
from Thermo Fisher Scientific were used for cloning, GoGreen® Taq polymerase from 
Promega was used to screen colonies for the presence of desired genes, and sequencing 
was performed at the University of Minnesota Genomics Center. 
GC/MS analysis of PaDa I activity against ∆6-protoilludene 
PaDa I – ∆6-protoilludene assays were set up in glass GC/MS vials as follows:  
10 mM Potassium Phosphate buffer pH 7.0: 564 µL 
1.9 mg/mL ∆6-Protoilludene synthase: 10 µL  
100 mM MgCl2 = 70 µL 
PaDa I (or negative control) concentrated supernatant = 25 µL  
FPP = 14 µL 
H2O2= 1.75 µL 
 
After shaking for 4 hours, the rubber septum of the GC/MS vial was pierced and a 
100 μM polydimethylsiloxane (PDMS) fiber was inserted into the headspace (for volatile 
analysis) or the reaction solution and allowed to sample for 10 minutes. The PDMS fiber 
was then inserted into the port of a HP GC 7890A Gas chromatograph coupled to a mass 
spectrometer with a HP MSD triple axis detector.  
PaDa I – limonene assays were set up in glass GC/MS vials as follows:  
Acetone : 240 µL 
Limonene : 0.23 µL 
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PaDa I (or negative control) concentrated supernatant : 15 µL  
H2O2 : 1 µL 
Fill to 400 µL with 10 mM Potassium phosphate pH 7.0  
 
Reactions were shaken overnight, extracted with a half of the reaction volume’s 
worth of hexane (1:2 extraction), and 1 μL of the hexane extract was deposited in the 
injection port by syringe. GC/MS programs were run in which the oven temperature 
began at 100 ˚C and reached 250 ˚C, for the volatile PaDa I – protoilludene sample and 
limonene sample this occurred over 15 minutes and for the PaDa I – protoilludene sample 
this occurred over 38 minutes.  
  
Results and Discussion 
Expression of Agrocybe aegerita unspecific peroxygenase mutant PaDa I 
The synthesized gene coding for the Agrocybe aegerita unspecific peroxygenase 
mutant PaDa I (hereafter referred to as PaDa I-UPO) was inserted into a pESC-ura 
expression vector under control of the GAL1 (galactose inducible) promoter, creating 
vector pESC-ura_PaDa_I. pESC vectors have been widely and successfully used for 
expression in S. cerevisiae39 and galactose inducible promoter based expression systems 
are among the strongest used in yeast.40  This, and the expression of PaDa I-UPO under 
the control of a GAL1 promoter in the original paper19 motivated the choice of expression 
vector. 
With pESC-ura_PaDa_I, PaDa I-UPO was expressed in the protease deficient S. 
cerevisiae strain BJ5465. The culture supernatant was assayed with ABTS and NBD 
reagents to determine peroxidase and mono(per)oxygenase activity, respectively. Both 
assays returned positive results for the PaDa I-UPO expression culture supernatant, and 
negative (no color) results for the same culture prior to galactose induction and for 
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expression supernatant from a BJ5465 culture containing empty pESC-ura. Thus, it 
appears that control of PaDa I-UPO is tight and the negative control has no activity. As 
shown in Table 2.3 below, PaDa I-UPO containing supernatant from this initial 
expression had 17% of the ABTS activity reported in the original paper.19  
 
Total activity (U/mL) of 
expression culture 
supernatant (first 
expression) 
Total activity (U/mL) of 
PaDa I-UPO expression 
culture supernatant from 
Molina-Espeja, et al.19  
Comparison of activity in 
expression culture 
supernatant to that reported 
in Molina-Espeja et al.19 (%)  
0.56 ± 0.045 3.4 17% 
 
Despite the presence of UPO activity in the expression culture supernatant and 
lack of activity in the empty vector control supernatant, SDS-PAGE analysis revealed no 
distinct protein bands between the two supernatants. In addition, in contrast to reported 
SDS-PAGE gels of PaDa I-UPO,19  a dark band was not observed in the supernatant at 
the expected weight of 51.1 kDa (Figure 2.2). 
 
 
 
 
 
 
 
Table 2.3 - Comparison of total activity of expression culture supernatant to 
reported activity. The number after the ± sign is the standard deviation. 
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Both the lack of a distinct band for PaDa I-UPO and the low activity of the 
supernatant (compared to reported activity) indicated that PaDa I-UPO was being 
produced in insufficient quantity. In order to increase PaDa I – UPO production, 
expression temperature and time of expression induction were varied as these variables 
have been shown to affect protein expression yield.41,42 One set of cultures was expressed 
at 25˚C (as in Molina-Espeja et al.)19 while another was expressed at 20˚C to determine 
whether a lower expression temperature could improve protein solubility. Minimal media 
cultures were used to inoculate expression cultures (containing galactose as inductant) 
after two, two and a half, and three culture doubling times (Figure 2.3).  
Figure 2.2 - SDS PAGE gels of first PaDa I-UPO expression A) this study (initial 
expression in BJ5465 protease deficient strain concentrated 72 x by filtration) and B) 
original study which produced PaDa I-UPO (from Molina-Espeja et al., 2014). In B) 
the band reported as PaDa I-UPO is located at approximately 50 kDa. 
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Following expression, cultures were tested for UPO activity with ABTS as the substrate 
(Table 2.4). 
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Figure 2.3 - Growth of S. cerevisiae BJ5465 cultures expressing PaDa I-UPO. A) 
Growth in minimal media of a representative culture. I, II, and III indicate induction 
at two, two and a half, and three doubling times respectively. B) Growth of expression 
culture at 25˚C and C) 20˚C, with a red triangle by a timepoint signifying time of 
supernatant harvest. Error bars represent standard deviation.  
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25˚C 
Culture    
1I 1II 1III 2I 2II 2III 3I 3II 3III 
Total 
activity 
(U/mL) 
1.43± 
0.0753  
1.28± 
0.0588 
1.04± 
0.12 
1.42± 
0.043 
1.12± 
0.046 
1.07± 
0.049 
1.18± 
0.057 
1.63± 
0.058 
0.938± 
0.077 
Culture 
at 20˚C 
1I 1II 1III 2I 2II 2III 3I 3II 3III 
Total 
Activity 
(U/mL) 
0.740± 
0.090  
1.01± 
0.065 
0.888± 
0.052 
1.04± 
0.003 
0.712± 
0.053 
1.03± 
0.032 
1.36± 
0.049 
1.33± 
0.058 
1.086± 
0.099 
 
For all cultures except 3I and 3III, cultures expressed at 25˚C had higher total 
activity than those expressed at 20˚C. Induction at timepoints I (two doubling times) and 
II (two and a half doubling times) in all cases had the highest total activity, with the 
culture 3II (at 25˚C) having the highest total activity (1.63 ± 0.058 U/mL, 47.9% of that 
reported in the initial paper).19 From this point onward, all PaDa I-UPO expressions were 
carried out at 25 ˚C and induced at timepoint I.  
 The supernatants of the most active cultures (1I, 1II, 2I, and 3II) were combined, 
concentrated by filtration, and analyzed by SDS-PAGE (Figure 2.4). 
 
 
 
 
Table 2.4 - Total activity (measured through activity on ABTS) of PaDa I-UPO 
expressing BJ5465 S. cerevisiae cultures. The number of each culture indicates the 
initial yeast colony used for inoculation (three replicates performed in total). The 
Roman numeral subscript of each culture indicates the timepoint of induction, with I, 
II, and III indicating induction at two, two and a half, and three doubling times 
respectively. The number after the ± symbol is the standard deviation.  
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Despite higher levels of ABTS activity, there was no distinct protein band 
observed near PaDa I – UPO’s expected molecular weight of 51.1 kDa (while a band is 
observed in most samples around 50 kDa,  in Figure 7 the same band is observed in the 
empty vector control).  
Attempts to purify PaDa I – UPO 
 In order to concentrate and partially purify the PaDa I-UPO protein, and thus 
observe a distinct PaDa I-UPO band, the PaDa I-UPO supernatant was fractionally 
precipitated with ammonium sulfate (Figure 2.5).  
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1 = Empty vector supernatant x 500 
2 = PaDa I-UPO supernatant x 500 
3 = Empty vector supernatant x 250 
4 = PaDa I-UPO supernatant x 250 
5 =Empty vector supernatant x 100 
6 =PaDa I-UPO supernatant x 100 
7 = Empty vector supernatant x 50 
8 = PaDa I – UPO supernatant x 50 
9 = PaDa I – UPO supernatant x 10 
Figure 2.4 - SDS-PAGE analysis of S. cerevisiae culture supernatant at various 
concentrations. “x” in the legend above indicates level of concentration by filtration.  
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1 = 40% precipitation, 
PaDa I-UPO 
2 = 40% precipitation, 
empty vector 
3 = 45% precipitation, 
PaDa I-UPO 
4 = 45% precipitation, 
empty vector 
5 = 50% precipitation, 
PaDa I-UPO 
6 = 50% precipitation, 
empty vector 
7 = 55% precipitation, 
PaDa I-UPO 
8 = 55% precipitation, 
empty vector 
9 = 60% precipitation, 
PaDa I-UPO 
10 = 60% 
precipitation, empty 
vector  
Figure 2.5 - SDS-PAGE analysis of PaDa I-UPO ammonium sulfate precipitation 
fractions. A) 30% precipitation followed by 60% precipitation and B) 30% 
precipitation (not shown) followed by successive precipitations to 60%. Percent of 
ammonium sulfate added is in w/v %. For a given experiment, all precipitations were 
performed successively on the same supernatant.  
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The resulting protein precipitates were too active to be measured with the ABTS 
assay, and were assayed against NBD instead (Table 2.5).  
 
w/v percent 
of  
ammonium 
sulfate for 
precipitation 
Unconcentrated  
supernatant 
30% 40% 45% 50% 55% 60% 
ΔOD425/min 
(NBD 
activity) 
0.006 
±0.01 
0.004 
±0.01 
0.29 
±0.052 
0.54 
±0.043 
0.157 
±0.022 
0.557 
±0.065 
0.49 
±0.012 
 
For comparison to total UPO activity as measured by ABTS, the unconcentrated 
supernatant used in these precipitations had a total activity of 0.942 ± 0.064 U/mL and 
the solution remaining after precipitation had a total activity of 0.00552 ± 0.00013 U/mL. 
From Figure 8A, it appears that much of the non-UPO protein in the supernatant is 
removed by 30% ammonium sulfate precipitation, while activity assays indicate that 
relatively little of the PaDa I-UPO protein is removed by 30% ammonium sulfate 
precipitation.  Subsequent precipitations with higher levels of ammonium sulfate 
contained high concentrations of PaDa I-UPO (the 45% fraction is 90 times as 
concentrated as the supernatant, Table 2.5) and contained far less protein overall than 
non-precipitated supernatant (compare Figures 2.4 and 2.5). It also appears nearly all 
PaDa I-UPO was removed from the supernatant following 60% ammonium sulfate 
precipitation, as the remaining supernatant has low ABTS activity. However, the same 
protein bands appear to be present in both the empty vector control and PaDa I-UPO 
samples across all precipitation fractions, thus no distinct PaDa I-UPO band can be found 
Table 2.5 - Activity of fractional ammonium sulfate precipitates on NBD. The 
number after the ± symbol is the standard deviation. 
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(Figure 2.5). It should be noted that Molina-Espeja et al. report an initial precipitation 
with 55% ammonium sulfate followed by a final cut of 85% ammonium sulfate, but 
experimentally the highest concentration of ammonium sulfate which could be dissolved 
in the supernatant was approximately 60% even with heating.  
Following ammonium sulfate precipitation, ion exchange chromatography was 
used in an attempt to purify PaDa I-UPO. Despite using both dialysis and desalting 
columns (independently) to remove ammonium sulfate, the protein appeared not to bind 
to the strong cation exchange column. This was determined by ABTS assays, which 
established that all UPO activity was in the first several fractions to come off of the 
column, following loading and before elution with NaCl. The UPO activity containing 
fractions were compared by SDS-PAGE to empty vector control samples also subjected  
to the same FPLC method, resulting in Figure 2.6 below. Both empty vector control and 
PaDa I-UPO had the same visible bands, similar to those seen in Figure 2.5. 
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Figure 2.6 - SDS-PAGE analysis of PaDa I-UPO and empty vector control FPLC 
fractions. Lanes 1-5 are PaDa I –UPO fractions, while lanes 6-9 are empty vector 
control 
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Expression of PaDa I-UPO with vertebrate and S. cerevisiae Kozak sequences 
In an attempt to increase PaDa I-UPO expression to a level observable by SDS-
PAGE, the Kozak sequence on pESC-ura_PaDa_I was examined. Kozak sequences are 
conserved in the vicinity of the start codon in eukaryotic mRNA, and are recognized as 
the translational initiation site by the ribosome. The strength of the Kozak sequence is 
important for determining the amount of protein which will be synthesized by the 
ribosome from an mRNA transcript,43 and thus the strength of the Kozak sequence in 
pESC-PaDa I could be adjusted to increase expression of PaDa I-UPO. The most 
common Kozak sequence identified in vertebrates is ACCATGG, 44 and this sequence is 
often used for heterologous expression in non-vertebrate hosts as it is very strong. Highly 
expressed genes in S. cerevisiae typically have the Kozak sequence AAAAAAATGTCT, 
making this a potentially useful sequence to test in heterologous expression along with 
the vertebrate Kozak sequence.45  
 In the area surrounding the start codon of PaDa I-UPO in pESC-ura_PaDa_I, no 
sequence similar to either the vertebrate or S. cerevisiae Kozak sequence was present. 
The surrounding sequence was CTAATGAAA (start codon underlined). In order to 
create a stronger Kozak sequence and increase production of PaDa I-UPO, site directed 
mutagenesis was used to produce six plasmids identical to pESC-ura_PaDa_I but with 
different Kozak sequences (Table 2.6).  
 
 
 30   
 
 
Plasmid  Sequence near start codon, altered Kozak sequence 
highlighted and start codon underlined 
pESC-ura_PaDaI_A1 CGACTCAACCATGGAA 
pESC-ura_PaDaI_A2 CGACTCAACCATGAAA 
pESC-ura_PaDaI_A3 CGACAAAAAAATGTCT 
pESC-ura_PaDaI_A4 CGACAAAAAAATGAAA 
pESC-ura_PaDaI_A5 CGACTCAATAATGTCT 
pESC-ura_PaDaI_A6 CGACTCAATAATGAAA 
 
pESC-ura_PaDaI_A1 contains the full vertebrate Kozak sequence, which alters 
the first amino acid of PaDa I-UPO from lysine to glutamic acid. pESC-ura_PaDaI_A2 
contains the vertebrate Kozak sequence but does not change lysine to glutamic acid. 
pESC-ura_PaDaI_A3 contains the full S. cerevisiae Kozak sequence, which changes the 
first amino acid of PaDa I-UPO from lysine to serine. pESC-ura_PaDaI_A4 contains the 
S. cerevisiae Kozak sequence, but does not change the first amino acid of PaDa I-UPO 
from lysine to serine. pESC-ura_PaDaI_A5 preserves the original surrounding sequence 
except for the third base in front of the start codon, which is switched from C to A, 
adenine at this position being the most crucial component of the Kozak sequence. pESC-
ura_PaDaI_A5 also changes the first amino acid of PaDa I-UPO from lysine to serine in 
order to be closer to the S. cerevisiae Kozak sequence. pESC-ura_PaDaI_A6 is the same 
as pESC-ura_PaDaI_A5, but does not change the first amino acid of PaDa I-UPO from 
lysine to serine.  
Table 2.6 - pESC-ura PaDa I plasmids with altered Kozak sequences. 
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Plasmids pESC-ura_PaDaI_A4 and pESC-ura_PaDaI_A5 could not be 
transformed into BJ5465 S. cerevisiae, while plasmids pESC-ura_PaDaI_A1, pESC-
ura_PaDaI_A2, pESC-ura_PaDaI_A3, and pESC-ura_PaDaI_A6 were transformed into 
BJ5465 S. cerevisiae and expressed. Supernatants were assayed for ABTS activity (Table 
2.7), and then concentrated by filtration for SDS-PAGE analysis (Figure 2.7). 
 
 
          
      
 
Plasmid contained in 
culture 
Total activity of supernatant (U/mL) 
pESC-ura_PaDaI_A1 No activity 
pESC-ura_PaDaI_A2 1.47 ± 0.0482 
pESC-ura_PaDaI_A3 No activity 
pESC-ura_PaDaI_A6 1.58 ± 0.040 
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1 = A2 supernatant x 50 
2 = A2 supernatant x 10 
3 = A2 supernatant x 1 
4 = A6 supernatant x 1 
5 = A6 supernatant x 10 
6 = A6 supernatant x 50 
7 = Empty vector 
supernatant x 1 
8 = Empty vector 
supernatant x 10  
9 = Empty vector 
supernatant x 50 
Figure 2.7 - SDS-PAGE analysis of concentrated expression supernatant from 
cultures containing pESC-ura PaDa I A2 and A6. The “x” in the legend above 
indicates level of concentration by filtration. Note: the figure above is composed of 
two independent gels which were run together.   
Table 2.7 - Total activities (determined by ABTS assay) of PaDa I-UPO 
supernatants expressed with modified Kozak sequences. The number after the ± 
symbol is the standard deviation. 
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 Only two of the expression cultures, those expressing PaDa I-UPO with Kozak 
sequences A2 and A6, were active, and these did not have significantly higher activity 
than PaDa I-UPO expressed with the native sequence (see Table 2.7). Both of the 
plasmids which altered the first amino acid of PaDa I-UPO from lysine to glutamic acid 
or serine had no activity, indicating that the presence of lysine in this position is crucial to 
PaDa I-UPO’s activity. As the supernatants from the two active cultures did not contain a 
distinct (i.e. not also seen in the empty vector control) protein band corresponding to 
PaDa I’s expected molecular weight of 51.1 kDa, it appears the use of modified Kozak 
sequences did not increase PaDa I-UPO expression.   
Modification of terpenes by PaDa I-UPO 
After repeated purification attempts, concentrated (but unpurified) supernatant 
with peroxidative and peroxygenase activity was assayed by GC/MS for activity against 
various terpenes. As A. aegerita UPO has previously been shown to modify limonene,23 
this substance was assayed first (see Figure 2.8). 
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Figure 2.8 - GC/MS analysis of PaDa I – UPO limonene reactions. A) reaction of 
limonene with empty vector control supernatant and B) reaction of PaDa I-UPO 
supernatant with limonene. A grey star indicates limonene, a red star indicates limonene 
epoxide, while a black triangle indicates carveol. All peak assignments were determined 
by comparison with the National Institute of Standards and Technology (NIST) 
molecular database.46 
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As reported in the literature for A. aegerita UPO, the PaDa I-UPO containing 
supernatant converted limonene to limonene epoxide and carveol.23 To determine 
whether PaDa I-UPO can modify sesquiterpene compounds, the PaDa I-UPO supernatant 
was assayed against Δ6-protoilludene, which was provided by co-reaction with Δ6-
protoilludene synthase. A peak with an m/z value of 220 was observed in both the liquid 
and headspace of the Δ6-protoilludene assay. As Δ6-protoilludene has an m/z value of 
204, this peak could be a Δ6-protoilludene derivative with an additional oxygen atom 
(MW of 16 g/mol). No peak with m/z of 220 was observed in the absence of Δ6-
protoilludene synthase, indicating Δ6-protoilludene must be present for the putatively 
modified compound to appear. (Figure 2.9 and 2.10). 
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Figure 2.9 - GC/MS analysis of Δ6-protoilludene and PaDa I-UPO reaction, 
liquid fraction. A) Δ6-Protoilludene synthase and empty vector supernatant B) 
Δ6-Protoilludene synthase and PaDa I-UPO supernatant C) FPP and PaDa I-
UPO. Red stars indicate Δ6-protoilludene (as determined by NIST database),46 and 
black triangles represent the putatively modified product with a molecular weight of 
220 g/mol.  
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Figure 2.10 - GC/MS analysis of Δ6-protoilludene and PaDa I-UPO reaction, volatile 
headspace. A) Δ6-Protoilludene synthase and empty vector supernatant B) Δ6-
Protoilludene synthase and PaDa I-UPO supernatant C) FPP and PaDa I-UPO.     
Red stars indicate Δ6-protoilludene (as determined by NIST database),46 and black 
triangles represent the putatively modified product with a molecular weight of 220 g/mol.  
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To determine if the reaction is dependent on H2O2, PaDa I – UPO was also 
assayed against Δ6-protoilludene at high (5x) H2O2 concentration and without H2O2 (see 
figure 2.11).  
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Figure 2.11. GC/MS analysis of Δ6-protoilludene and PaDa I-UPO reaction, 
volatile headspace. A) Reaction with 5x increased H2O2 B) Reaction without 
H2O2. Red stars indicate Δ6-protoilludene (as determined by NIST database)  
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As expected for hydrogen peroxide dependent UPO, no modified product is 
observed in the absence of H2O2.  Increasing the level of H2O2 in the reaction also 
resulted in an absence of modified product. This is in accordance with established 
literature, as increased H2O2 has been shown to inactivate A. aegerita UPO, most likely 
by the production of hydroxyl radicals which react with the heme of the active site and 
produce biliverdin.47 Even for reactions with the level of H2O2 used for the GC/MS 
assays shown above, this heme inactivation or “heme bleaching,” along with the intrinsic 
catalase activity of UPO, could account for the fact that the modified Δ6-protoilludene 
peak is considerably smaller than the unmodified peak.  
In addition, PaDa I – UPO was assayed against another sesquiterpene, valencene, 
using the same procedure used for limonene. Initially three sesquiterpenes, 
caryophyllene, humulene, and valencene were to be assayed, but the caryophyllene and 
humulene in our possession had already become oxidized in the bottle. No activity was 
observed for PaDa I – UPO against valencene (see supplementary materials).  
Conclusion 
Based on ABTS and NBD assays for peroxidative and peroxygenase activity, 
respectively, it appears that PaDa I-UPO was successfully expressed in S. cerevisiae. The 
highest activity against ABTS achieved in any culture was 1.63 ± 0.058 U/mL, 47.9% of 
that reported in the literature.19 In addition, culture supernatant modified limonene to 
limonene epoxide and carveol (as shown in the literature),23 and appears to have activity 
against Δ6-protoilludene. According to GC/MS analysis, a compound with a molecular 
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weight of 220 g/mol is produced, which is consistent with the addition of an oxygen atom 
to Δ6-protoilludene. Despite this activity, SDS-PAGE analysis revealed that the PaDa I-
UPO supernatant and empty vector control supernatant had the same visible protein 
bands. Altering expression conditions such as temperature and time of induction, and 
adding Kozak sequences based on the vertebrate and S. cerevisiae sequences did not 
significantly increase PaDa I-UPO production, or  cause a distinct PaDa I-UPO protein 
band to appear. No band was revealed either by concentration and purification with 
ammonium sulfate precipitation or ion exchange chromatography.  
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Chapter 3 
Expression of fungal flavin binding enzymes in E. coli 
Introduction 
Flavin dependent monooxygenases (FMOs) catalyze the transfer of an atom of 
molecular oxygen to a substrate molecule, while the other oxygen atom is reduced to 
water. In nature, FMOs are involved in catabolism, hormone biosynthesis, vitamin and 
antibiotic production, and defense .48 They are known to catalyze a variety of reactions, 
including hydroxylation, epoxidation, Baeyer–Villiger oxidation, sulfoxidations, and 
halogenations. These oxidation reactions would be either impossible or very difficult to 
achieve by organic chemical synthesis.49 Because of this, and because of their high 
enantio- and regio- selectivity, FMOs have attracted the attention of the pharmaceutical, 
fine-chemical and food industries. 
The gene cluster around Omp7 protoilludene synthase in Omphalatus olearius 
contains an enzyme called Omp7a,16 which has been identified through bioinformatics to 
be a FAD binding oxidoreductase. In addition, Omp7a has been co-expressed with the 
∆6-protoilludene synthase Omp7 in S. cerevisiae, and appears to have some activity, 
producing a non-volatile compound that degrades in the GC/MS (unpublished data).  The 
Stehi 7 protoilludene synthase gene cluster in Stereum hirsutum contains a number of 
enzymes17 which have been identified by bioinformatics as potential scaffold modifiers. 
These include the FAD binding oxidoreductases FAD1 and FAD2, the GMC (glucose-
methanol-choline oxidase) oxidoreductase GMC2, and the reductase RED1.  
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Note that the GMC superfamily are flavoprotein oxidoreductases.50 In fungi, 
genes involved in secondary metabolite biosynthesis are clustered together on the 
genome.51 Thus the presence of flavin binding genes in Δ6-protoilludene synthase gene 
clusters indicate that the flavin binders are likely part of terpenoid biosynthesis. 
Presumably, they modify the Δ6-protoilludene scaffold. As the CYPs of these gene 
clusters have proven difficult to isolate, it is worthwhile attempting to isolate other Δ6-
protoilludene modifying enzymes for use in an in vitro terpenoid biocatalytic pathway. 
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A = Glycosyl hydrolase  I = CYP (cytochrome P450) 
B = Acyl-CoA transferase   J = Reductase (RED1) 
C = Outer membrane protein   K = CYP 
D = Aspartate aminotransferase L = GMC oxidoreductase (GMC2) 
E = Stehi7 protoilludene synthase  M = FAD binding oxidoreductase (FAD1)  
F = Aldo-keto reductase   N = FAD binding oxidoreductase (FAD2) 
G = GMC oxidoreductase  O = Aldo-keto reductase 
H = Major facilitator superfamily  P = CYP 
(MFS) transporter  
 
 
 
Figure 3.1. Stehi7 biosynthetic gene cluster. 17 Stehi7 protoilludene synthase is 
pictured above in red, CYPs in the gene cluster are in yellow, flavin binding enzymes 
investigated in this study are in green, all other genes of the cluster are in blue.  
A = FAD-binding oxidoreductase (Omp7a)     B = CYP      C = Omp7 protoilludene 
synthase 
 
 
 
A B C 
Figure 3.2. Omp7 biosynthetic gene cluster.16 Omp7 protoilludene synthase is in 
red, Omp7a (investigated in this study) is in green, and CYPs are yellow. 
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The key to the oxygenase activity of FMOs is the flavin prosthetic group itself, 
which during the reaction becomes a flavin C4a-oxygen adduct and transfers oxygen to 
the substrate.52 In most FMOs the flavin cofactor is non-covalently, but tightly, bound to 
the apoenzyme and the two can be disassociated.49 However, some flavoenzymes are 
attached to their flavin cofactor by one or two covalent linkages.53  
The general mechanism of the flavin dependent monooxygenase reaction cycle is 
shown below. The reaction of the reduced flavin with oxygen results in formation of the 
nucleophilic flavin C4a-peroxide species or the electrophilic C4a-hydroperoxide species, 
which then react with either an electrophilic or nucleophilic substrate molecule, 
respectively. Once oxygen is transferred to the substrate hydroxyflavin forms. Loss of 
water then produces oxidized flavin, which is reduced in a critical step to restart the 
cycle.48  
 
Figure 3.3. The general mechanism of the flavin dependent monooxygenase reaction 
cycle48 
 43   
 
Flavoenzymes can be divided into groups based on whether they utilize NAD(P)H 
as an external electron donor, use a flavin reductase partner to reduce flavin, or reduce 
the flavin cofactor through substrate oxidation.48 As the largest group of FMOs utilize a 
flavin reductase to reduce flavin, the E. coli flavin reductase (Fre) will overexpressed in 
E. coli so that it can be used in vitro.  
Materials and Methods 
Transfer of flavin binding enzymes and E. coli Fre to pCuminBB plasmids.  
In order to obtain the E. coli flavin reductase (Fre) gene, a Top10 E. coli culture 
was grown overnight at 37 ˚C and 220 RPM. The E. coli genomic DNA was extracted 
with a Promega Wizard® DNA purification kit. Primers to amplify E. coli Fre from 
gDNA were based on the E. coli Fre sequence reported by Spyrou et al.,54 while the other 
flavin binding enzymes were amplified from plasmids in the Schmidt-Dannert collection 
(see Table 3.1). FAD1, FAD2, GMC2, RED1, Omp7a, and E. coli Fre were cloned into 
pCuminBB plasmids, Fre with an N-terminal histidine tag and the other enzymes with C-
terminal histidine tags. Cloning was performed by Hifi assembly (using the online 
NEBuilder® assembly tool to design primers, the NEBuilder® HiFi DNA Assembly kit 
and NEB’s protocols), or with restriction digestion and ligation (see Table 3.2). Primers 
were ordered from Integrated DNA Techologies.  Thermo Fisher Scientific Top10® cells 
were used for plasmid production during cloning, GoGreen® Taq polymerase from 
Promega was used to screen colonies for desired genes, and sequencing was performed at 
the University of Minnesota Genomics Center. pCuminBB plasmids containing FAD-
binding enzymes were transformed into C2566 E. coli cells for protein expression.  
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Plasmid name Gene and promoter information Selectable marker Source 
pCuminBB-ctH6 Contains cumate promoter, 
histidine tag for protein C-
terminus 
Ampicillin 
resistance 
From Maureen 
Quin (CSD lab) 
pUCBB-FAD1      Contains FAD1 gene  Ampicillin 
resistance 
From Christopher 
Flynn (CSD lab) 
pUCBB-FAD2 Contains FAD2 gene Ampicillin 
resistance 
From Christopher 
Flynn (CSD lab) 
pCR-Blunt-GMC2 TOPOTM (Thermofisher 
Scientific) vector containing 
GMC2 gene 
Kanamycin and 
zeocin resistance 
From Christopher 
Flynn (CSD lab) 
pCR-Blunt-RED1 TOPOTM vector containing 
RED1 gene 
Kanamycin and 
zeocin resistance 
From Christopher 
Flynn (CSD lab) 
pESC-His-Omp7a Contains Omp7a Ampicillin 
resistance, HIS3* 
Marker 
From Sarah 
Perdue (CSD lab)  
pCuminBB-cHis-
FAD1 
Contains ct-His**-FAD1 gene 
under control of cumate promoter 
Ampicillin 
resistance 
This study 
pCuminBB-cHis-
FAD2 
Contains ct-His-FAD2 gene 
under control of cumate promoter 
Ampicillin 
resistance 
This study 
pCuminBB-cHis-
GMC2 
Contains ct-His-GMC2 gene 
under control of cumate promoter 
Ampicillin 
resistance 
This study 
pCuminBB-cHis 
RED1 
Contains ct-His-RED1 gene 
under control of cumate promoter 
Ampicillin 
resistance 
This study 
pCuminBB-cHis 
Omp7a 
Contains ct-His-Omp7a gene 
under control of cumate promoter 
Ampicillin 
resistance 
This study 
pCuminBB-ntH6 Contains cumate promoter, 
histidine tag for protein N-
terminus 
Ampicillin 
resistance 
From Maureen 
Quin (CSD) lab 
pCuminBB-nHis-
E.coli-Fre 
Contains nt-His***-Fre (E.coli 
flavin reductase) gene under 
control of cumate promoter 
Ampicillin 
resistance 
This study 
pCuminBB-nHis-
E.coli-Fre 
 ATG-onlyb4his 
Contains nt-His-Fre gene under 
control of cumate promoter. 
Native start codon of Fre 
removed 
Ampicillin 
resistance 
This study 
Strain Description Source 
Top10 Chemically competent E. coli 
strain used for plasmid 
production 
ThermoFisher Scientific  
C2566 E. coli strain used for protein 
expression 
New England Biolabs (NEB) 
*HIS3 allows growth on minimal media without added histidine. 
**ct-His indicates the protein has a C-terminal histidine tag 
***nt-His indicates the protein has an N-terminal histidine tag 
 
Table 3.1 – Plasmids and strains used in Chapter 3 
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Primer name 5’ – 3’ Sequence Function 
FAD1 F* GGATCCATATGCCTGGCAAAC
TCAATG 
Amplifies FAD1 from pUCBB-FAD1, 
amplicon is cut with NdeI  and NotI 
restriction enzymes, ligated into cut  
pCuminBB-ctH6 vector to produce 
pCuminBB-cHis-FAD1 
FAD1 R GTAGTGCGGCCGCGGCAGCA
ACAGGCCTGTC 
FAD2 F GGATCCATATGGCATCGGAA
AAGAACTCTC 
Amplifies FAD2 from pUCBB-FAD2, 
amplicon is cut with NdeI  and NotI 
restriction enzymes, ligated into cut  
pCuminBB-ctH6 vector to produce 
pCuminBB-cHis-FAD2 
FAD2 R CCAGTGCGGCCGCGAAATGC
CATCCTCCTGC 
GMC2 F CTGATGTCGACATGTCTCTTT
CACCGTCCTTG 
Amplifies GMC2 from PCR-Blunt-GMC2, 
amplicon is cut with SalI  and NotI 
restriction enzymes, ligated into cut  
pCuminBB-ctH6 vector to produce 
pCuminBB-cHis-GMC2 
GMC2 R CCAGTGCGGCCGCTAGCTCTC
CTGCTTGACGTG 
A11F AGCAGCGGCCATCATCAT  Linearizes pCuminBB-ctH6 for HiFi 
assembly of RED1 and Omp7a  A7R GGATCCAGATCCCTCCTTC 
A9F CGAAGGAGGGATCTGGATCC
ATGTCCTCTCACTCTGCAG 
Amplifies RED1 from PCR-Blunt-RED1, for 
HiFi assembly to produce pCuminBB-cHis 
RED1 A13R ATGATGGCCGCTGCTGCTGCC
GCGCGGCACCAGGGATCCTG
ACAAAGCGATGTCGAC 
A10F CGAAGGAGGGATCTGGATCC
ATGTCTGCTCCTGCTTCTTTCA
C 
Amplifies Omp7a from  pESC-His-Omp7a 
for HiFi assembly to produce pCuminBB-
cHis Omp7a 
A14R ATGATGGCCGCTGCTGCTGCC
GCGCGGCACCAGGGATCCCA
CGGAAATCGGGCACCA 
A21F ATATGGGCGGTTGATAAGAT
ATC     
Linearizes pCuminBB-ntH6 for HiFi 
assembly of E. coli Fre 
A21R GGATCCGCTGCCGCGCGG 
A22F CCTGGTGCCGCGCGGCAGCG
GATCCATGACAACCTTAAGCT
GTAAAG 
Amplifies E. coli Fre from E. coli genomic 
DNA for HiFi assembly to produce 
pCuminBB-nHis-E.coli-Fre 
  A22R TCGATATCTTATCAACCGCCC
ATATTCAGATAAATGCAAAC
GC 
A23F CCTGGTGCCGCGCGGCAGCG
GATCCACAACCTTAAGCTGTA
AAGTG 
Amplifies E. coli Fre from E. coli genomic 
DNA for HiFi assembly to produce 
pCuminBB-nHis-E.coli-Fre- ATG-onlyb4his 
A23R TCGATATCTTATCAACCGCCC
ATATTCAGATAAATGCAAAC
GC 
* = F indicates forward primer, R indicates reverse primer 
 
Table 3.2 – Primers used in Chapter 3 
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Expression of flavin-binding enzymes in E. coli  
 A C2566 E. coli colony containing the desired plasmid (ampicillin resistant) was 
picked from a selective plate and used to inoculate a 4 mL culture of lysogeny broth (LB) 
containing 100 μg/mL of ampicillin. LB contained 10 g of Bacto-tryptone, 5 g of yeast 
extract, and 5 g of NaCl per liter. This culture was grown overnight at 37 ˚C and 220 
RPM. The following morning an amount of starter culture equal to 1/100th of the 
expression culture’s volume was used to inoculate an LB expression culture containing 
100 μg/mL of ampicillin. Unless otherwise noted, expression cultures were 4 mL. 
Expression cultures were grown until they reached an OD600 of 0.4-0.5, upon reaching 
which protein production was induced by addition of cumate (ρ-isopropylbenzoate) from 
a 50 mM cumate stock in ethanol.  
 The expression cultures were grown at 37 ˚C (unless otherwise noted) and grown 
overnight (approximately 16 hours), unless otherwise noted. To harvest the cells and test 
protein expression level, 1 mL of each expression culture was taken, spun down at 13000 
rpm for 1 minute, the supernatant was removed, and the resulting cell pellet was 
resuspended in 300 µL of Bugbuster® protein extraction reagent for lysis. The lysis 
reactions were left at room temperature (with occasional shaking) for 20 minutes, and 
then 15 µL of the lysis solution was removed and labeled the “total protein fraction”. The 
remaining solution was spun down at 13000 rpm for 5 minutes, resulting in clear 
supernatant and a cell pellet. 15 µL of the clear supernatant was removed and labeled the 
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“soluble protein fraction.” The protein expression level was determined by SDS-PAGE 
analysis, and with staining in Coomassie Biosafe® stain overnight. 
Co-expression of flavin binding enzymes with chaperone proteins in E. coli.  
 FAD1, GMC2, and RED1 were each co-expressed in C2566 E. coli cultures with 
the molecular chaperones of the Takara Chaperone Set. Takara has included a very 
detailed protocol in their Chaperone Plasmid Set Product Manual (Cat #3340) for how to 
perform coexpression of the chaperones and a target protein. This protocol was adapted 
to the 4 mL expression performed with the flavin binding enzymes (described in the 
section immediately above) and performed at 37 ˚C.  
Results and Discussion 
Expression of flavin-binding enzymes with varying inductant concentrations 
Genes encoding the flavin-binding enzymes FAD1, FAD2, GMC2, RED1, and 
Omp7a were obtained from plasmids in the Schmidt-Dannert plasmid collection (see 
Table 3.2), while the gene encoding E. coli FAD-reductase (Fre) was amplified from 
extracted E. coli genomic DNA. The E.coli Fre gene was inserted into a pCumin plasmid 
with an N-terminal histidine tag, while the other flavin binding enzymes were inserted 
into pCumin plasmids with C-terminal histidine tags. pCumin plasmids use the cumate 
inducible system, which contains a strong constitutive promoter and an operator (CuO) 
that is bound by the repressor CymR. Upon addition of the inductant cumate (ρ-
isopropylbenzoate), repression is lifted.55 As the N-terminal histidine tag contains its own 
start codon, it is possible that the ribosome could start translation at the start codon of E. 
coli Fre proper and not include the histidine tag. Because of this, plasmids containing N 
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terminally histidine tagged Fre with and without a separate start codon before the Fre 
gene were made. Expressions were performed at 37˚C with 50 μM cumate, and both 
soluble and total (containing soluble and insoluble) protein fractions were analyzed by 
SDS-PAGE (Figure 3.4 and Table 3.3). 
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enzyme 
GMC2 FAD1 FAD2 RED1 Omp7a E. coli 
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Molecular 
Weight  
68.5 kDa 52.2 kDa 57.3 kDa 32.6 kDa 49.8 kDa 26.2 kDa 
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Figure 3.4. SDS-PAGE analysis of flavin-binding enzyme expression at 37 ˚C and 
50 μM cumate A) total and B) soluble protein fractions. Refer to Table 3.3 for 
expected molecular weights of FAD binding enzymes. Note, these expressions were 
performed in 500 mL cultures.   
1 = FAD1, 2 = FAD2, 3 = GMC2, 4 = RED1, 5 = Omp7a, 6 = E. coli Fre w/ATG,     
7 = E. coli Fre w/out ATG, 8 = Empty pCuminBB-cHis (negative control) 
                   1    2    3     4    5    6    7     8                            1            2      3     4     5     6      7     8 
Table 3.3. Expected molecular weights of FAD binding enzymes. Calculated using 
ExPASy® program  
  .  
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Protein bands corresponding to FAD1, GMC2, RED1, and both E. coli Fre with 
and without its own start codon are visible at approximately the expected molecular 
weights in the insoluble fraction, but not in the soluble fraction, indicating that these 
proteins are expressed but insoluble. The insoluble protein band for E. coli Fre with its 
own start codon is considerably stronger than that seen when only the start codon before 
the N terminal histidine tag is present, indicating that the presence of a start codon 
immediately before Fre proper increases expression.  A faint band is seen for Omp7a 
between 37 and 50 kDa in the insoluble fraction, indicating this protein may possibly be 
expressed insolubly, but very poorly. Both soluble and insoluble fractions for FAD2 
expression contained no bands distinct from the empty vector control, indicating this 
protein is not expressed.   
 The expression of proteins as insoluble inclusion bodies is often due to protein 
synthesis being faster than protein folding, resulting in high concentrations of unfolded 
protein which aggregate due to the exposure of normally buried hydrophobic residues.41 
Slowing down protein synthesis can result in increased solubility, and this is often 
accomplished by decreasing expression temperature and decreasing the concentration of 
inductant41,42 As cumate is the inductant for the flavin-binding enzyme expression 
system, the strongly expressed proteins (FAD1, GMC2, RED1, and E. coli Fre) were 
expressed with varying levels of cumate to determine if a certain concentration would 
yield soluble protein (Figure 3.5). 
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IV 
Figure 3.5. SDS-PAGE analysis of flavin-binding enzyme expression at 37 ˚C and 
a range of cumate concentrations. A) FAD1 expression B) GMC2 expression     
C) E. coli Fre expression D) RED1 expression. See Table 3.3 for expected 
molecular weights of flavin-binding enzymes. Concentrations of cumate used in each 
expression are shown in the legend above, and whether the protein fraction is soluble 
or total is indicated in parenthesis.  
  .  
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 For FAD1, GMC2, and RED1, significant protein expression in the total protein 
fraction occurs at 20 μM cumate, increases with increasing cumate concentration, and is 
strongest at 50 μM cumate. However, FAD1, GMC2, and RED1 do not express in soluble 
form at any cumate concentration. In contrast, E. coli Fre appears to express at 0 μM 
cumate, with expression apparent in all cultures (even those not containing the Fre 
pCumin expression plasmid), and expression decreases as cumate concentration is 
increased.  
Variation of expression temperature and induction time 
 As expression of flavin-binding enzymes is strongest at 50 μM cumate, and lower 
concentrations of cumate do not increase solubility, expressions were carried out with 50 
μM cumate while altering other variables. Two expressions were performed at 37 ˚C and 
induced at high (OD600 = 0.8) and low (OD600 = 0.3) cell density (Figure 3.6). In 
addition, expressions were performed at three lower temperatures: 16 ˚C, room 
temperature, and 30 ˚C (Figures 3.7-3.9).   
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Altering the induction point does not appear to produce any soluble FAD1, 
GMC2, or E. coli Fre. However, a faint band is present in both of the RED1 soluble 
fractions at approximately the expected molecular weight of 32.6 kDa. It should be noted 
that the soluble fractions for RED1 have a number of bands at various molecular weights 
that are not normally seen or seen so darkly, thus this is not conclusive proof of RED1 
being expressed in soluble form. 
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1 = FAD1 (soluble), 2 = GMC2 (soluble), 3 = RED1 (soluble), 4 = E. coli Fre 
(soluble), 5 = empty pCuminBB-cHis (soluble), 6 = FAD1 (total), 7 = GMC2 (total), 
8 = RED1 (total), 9 = E. coli Fre (total), 10 = empty pCuminBB-cHis (total) 
 Figure 3.6 - SDS-PAGE analysis of flavin-binding enzyme expression at 37 ˚C. A) 
Induced at OD600 = 0.8 B) induced at OD600 = 0.3 See Table 3.3 for expected 
molecular weights of flavin-binding enzymes. Whether the protein fraction is soluble 
or total is indicated in parenthesis.  
  .  
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(soluble), 5 = empty pCuminBB-cHis (soluble), 6 = FAD1 (total), 7 = GMC2 (total), 
8 = RED1 (total), 9 = E. coli Fre (total), 10 = empty pCuminBB-cHis (total) 
 Figure 3.7 - SDS-PAGE analysis of flavin-binding enzyme expression at 50 μM 
cumate and 30˚C. A) Harvested 16 hours post induction (overnight) and B) 32 
hours post induction. See Table 3.3 for expected molecular weights of flavin-binding 
enzymes. Whether the protein fraction is soluble or total is indicated in parenthesis.  
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1 = FAD1 (soluble), 2 = GMC2 (soluble), 3 = RED1 (soluble), 4 = E. coli Fre 
(soluble), 5 = empty pCuminBB-cHis (soluble), 6 = FAD1 (total), 7 = GMC2 (total), 
8 = RED1 (total), 9 = E. coli Fre (total), 10 = empty pCuminBB-cHis (total) 
 Figure 3.8 - SDS-PAGE analysis of flavin-binding enzyme expression at 50 μM 
cumate and room temperature. A) Harvested 16 hours post induction and B) 32 
hours post induction. See Table 3.3 for expected molecular weights of flavin-binding 
enzymes. Whether the protein fraction is soluble or total is indicated in parenthesis.  
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Figure 3.9 - SDS-PAGE analysis of flavin-binding enzyme expression at 50 μM 
cumate and 16 ˚C. A) Harvested 24 hours post induction, B) 48 hours post 
induction, C) 60 hours post induction and D) 72 hours post induction. See Table 
3.3 for expected molecular weights of flavin-binding enzymes. Whether the protein 
fraction is soluble or total is indicated in parenthesis.  
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 For both time points of the 30 ˚C and room temperature expressions, only RED1 and 
E.coli Fre appear to be expressed in the total protein fraction, and none of the flavin-
binding enzymes are expressed in soluble form. At 16˚C, only E. coli Fre is expressed. 
However, it does appear to be expressed in the soluble fraction, with soluble expression 
reaching a significant level at 48 hours, maximum level at 60 hours, and decreasing by 72 
hours. E. coli Fre appears to be expressed quite well in the total protein fraction, despite 
50 μM cumate being used, which is somewhat in contrast to the results reported in Figure 
3.5 (in which Fre expression decreased with increasing cumate concentration).  
Co-expression of flavin-binding enzymes with chaperone proteins 
 Molecular chaperones are proteins which assist in the correct folding of other proteins. In 
E. coli, GroEL, GroES, DnaK, DnaJ, GrpE and trigger factor (Tf) are important 
chaperone proteins, GroEL working in conjunction with GroES (GroEL-GroES system) 
and DnaK, DnaJ, and GrpE forming another team (DnaK-DnaJ-GrpE system).  When co-
expressed with heterologous proteins, these chaperones have been shown to aid in the 
folding of recombinant proteins and in a number of cases cause them to be expressed in 
soluble form.56,57,58 Takara® has produced a set of plasmids encoding different 
combinations of these chaperones (see Table 3.4 below), and these were co-expressed 
with the flavin-binding enzymes FAD1, GMC2, and RED1. Expression cultures were 
analyzed by SDS-PAGE. Note: Expressions of chaperone proteins alone established that 
the proteins from plasmid C3 (Table 3.5) did not express. Also, as RED1 appeared to 
possibly express in the soluble fraction of both high and low induction expressions 
(without chaperones) (see previous section), this expression was repeated. 
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Plasmid # C1 C2 C3 C4 C5 
Chaperone 
proteins 
expressed on 
plasmid 
DnaK-DnaJ-GrpE 
GroES-GroEL 
GroES-
GroEL 
DnaK-DnaJ-
GrpE 
GroES-
GroEL-Tf 
Tf 
Expected SDS-
PAGE Bands 
70, 60, 40, 22/29, 
and 10 kDa 
60 and 
10 kDa 
70, 40, and 
22/29 kDa 
60, 56, and 10 
kDa 
56 
kDa 
 
       
 
 
After 16 hours, cultures were analyzed to determine if expression was occurring, with 
FAD1 and chaperone co-expressions analyzed (Figure 3.10). By this timepoint, it 
appeared that FAD1 was not expressed (no band observed at FAD1’s expected molecular 
weight) and expressions were continued, with cultures analyzed again at 24 (Figure 3.11) 
and 48 hours (Figure 3.12) post induction.  
Chaperone 
Protein 
GroEL GroES DnaK DnaJ GrpE Tf 
Approximate 
Molecular 
Weight 
60 kDa 10 kDa 70 kDa 40 kDa 22 kDa (may appear 
around 29 kDa) 
56 kDa 
Table 3.5 - Takara® chaperone protein expression plasmids.55,56 
 
 
Table 3.4 - Molecular weights of Takara® chaperone proteins.55,56 
 
 
1 = C1+FAD1(sol)  8 = C1 + FAD1(total) 
2 = C2+FAD1(sol) 9 = C2+FAD1(total) 
3 = C3+FAD1(sol) 10 = C3+FAD1(total) 
4 = C5+FAD1(sol) 11 = C5+FAD1(total)   
5 = High RED1(sol) 12 = Low RED1(total)  
6 = Low RED1(sol) 13 = High RED1(total) 
7 = Empty (sol) 14 = Empty (total) 
 
 
 1    2    3    4    5    6    7    8    9  10   11  12  13 14        
Figure 3.10 - SDS-PAGE analysis of FAD1 expression and chaperone co-
expression at 16 hours post induction. See Tables 3.4 and 3.5 for expected 
molecular weights of chaperone proteins and chaperone plasmid descriptions. FAD1 
Expected MW = 52.2 kDa. Note: total = total protein, sol = soluble protein. 
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 1            2    3    4    5    6     7    8     9    10   11  12        
1 = C1+FAD1(total)  8 = C2+Empty(total) 
2 = C1+GMC2(total) 9 = C3+FAD1(total) 
3 = C1+RED1(total) 10 =C3+GMC2(total) 
4 = C1+Empty(total) 11 =C3+RED1(total)   
5 = C2+FAD1(total) 12 =C3+Empty(total)  
6 = C2+GMC2(total) 13 =C5+FAD1(total) 
7 = C2+RED1(total) 14 = Empty (total) 
 
 
1 = C5+GMC2(total) 8 = C1+GMC2(sol) 
2 = C5+RED1(total) 9 = C1+RED1(sol) 
3 = C5+Empty(total) 10 = C1+Empty(sol) 
4 = High RED1(total) 11 =C2+FAD1(sol)   
5 = Low RED1(total) 12 = Empty(sol)  
6 = Empty(total)  
7 = C1+FAD1(sol)  
 
 
1 = C2+GMC2(sol)  8 = C5+FAD1(sol) 
2 = C2+RED1(sol)  9 = C5+GMC2(sol) 
3 = C2+Empty(sol) 10 =C5+RED1(sol) 
4 = C3+FAD1(sol) 11 =C5+Empty(sol)   
5 = C3+GMC2(sol) 12 = High RED1(sol)  
6 = C3+RED1(sol) 13 = Low RED1(sol) 
7 = C3+Empty(sol) 14 = Empty (sol) 
 
 Figure 3.11 - SDS-PAGE analysis of flavin-binding enzyme and chaperone co-
expression at 24 hours post induction (PI). See Tables 3.3, 3.4, and 3.5 for expected 
molecular weights and chaperone plasmid descriptions. Note: total = total protein,      
sol = soluble protein. Red box indicates potential RED1 soluble expression.  
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7 = C5+FAD1(sol) 
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Figure 3.12 - SDS-PAGE analysis of flavin-binding enzyme and chaperone co-
expression at 48 hours PI. See Tables 3.3, 3.4, and 3.5 for expected molecular 
weights and chaperone plasmid descriptions. Total=total protein, sol = soluble protein. 
   
1 = C1+FAD1(total)  8 = C2+Empty(total) 
2 = C1+GMC2(total) 9 = C3+FAD1(total) 
3 = C1+RED1(total) 10 =C3+GMC2(total) 
4 = C1+Empty(total) 11 =C3+RED1(total)   
5 = C2+FAD1(total) 12 =C3+Empty(total)  
6 = C2+GMC2(total) 13 =C5+FAD1(total) 
7 = C2+RED1(total) 14 = Empty (total) 
 
 
1 = C5+GMC2(total) 8 = C1+GMC2(sol) 
2 = C5+RED1(total) 9 = C1+RED1(sol) 
3 = C5+Empty(total) 10 = C1+Empty(sol) 
4 = High RED1(total) 11 =C2+FAD1(sol)   
5 = Low RED1(total) 12 = C2+GMC2(sol)  
6 = Empty(total)         13 = Empty(sol)  
7 = C1+FAD1(sol)  
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 By 16 hours post induction, chaperone proteins appear to be expressed, however, 
there is no indication that flavin-binding enzymes are expressed even at 48 hours post 
induction. Thus, it would appear that chaperone expression inhibits flavin-binding 
enzyme co-expression. It should be noted that in lanes 11 and 12 of Figure 3.12 B (48 
hours post induction), soluble bands appear that do not appear in other GroES-GroEL 
expressions. However, given the molecular weight of the bands (clearly higher than 50 
kDa, probably approximately 60 kDa), this is likely soluble GroEL and not soluble FAD1 
or GMC2. In the total protein fractions of the same expression (see lanes 5-8 of Figure 
3.12 A), only the FAD1 and GMC2 GroEL-GroES coexpressions contain bands at the 
expected weight of GroEL. However, RED1 alone in high and low induction expressions 
(Expected MW = 32.6 kDa) does appear to be expressed by 24 hours (Figure 3.11 B lanes 
4 and 5). The presence of a faint band (not present in the negative control, marked by a 
red box on gel) at the expected molecular weight in the soluble fractions (Figure 3.11 C 
lanes 12-14) indicates RED1 may be expressed in soluble form under these conditions, 
and thus purification could be attempted.  
Conclusion 
Initial expressions of flavin-binding enzymes from the Stehi7 gene cluster under 
the control of the cumate promoter resulted in no expression for FAD2, little to no 
expression for Omp7a, insoluble inclusion bodies for FAD1, GMC2, RED1, and E. coli 
Fre, and no soluble protein of any kind. In order to cause soluble expression, inductant 
(cumate) level, expression temperature, induction time, and expression time were varied. 
Varying the level of cumate used caused the total protein expression to vary in a roughly 
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proportional manner for the flavin-binding enzymes FAD1, GMC2, and RED1, but did 
not increase their solubility. 
 Interestingly, E. coli Fre appeared to be strongly expressed in all cultures (both 
those containing and not containing an E. coli Fre cumate inducible plasmid) without 
cumate, with expression decreasing at higher cumate levels. However, subsequent 
cultures with high levels (50 μM) of cumate still expressed Fre strongly. When cultures 
were grown at 16 ˚C, Fre expression at 50 μM cumate resulted in significant soluble Fre 
presence after 48 hours. Performing expressions at high and low induction points appears 
to potentially result in low levels of soluble RED1 protein, thus purification of RED1 and 
Fre can be attempted. Coexpression of FAD1, GMC2, and RED1 with the chaperone 
proteins GroEL, GroES, DnaJ, DnaK, GrpE, and Tf was also attempted in order to assist 
with folding and obtain soluble protein. However, it appears that coexpression with these 
chaperones inhibits flavin-binding enzyme expression.  
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Chapter 4: Conclusions and Future Directions 
In pursuit of achieving in vitro biocatalysis of terpenoid compounds, an Agrocybe 
aegerita unspecific peroxygenase mutant (PaDa I-UPO) and flavin-binding enzymes 
from Stehi7 (Stereum Hirsutum) and Omp7 (Omphalatus olearius) Δ6-protoilludene 
synthase gene clusters were expressed in S. cerevisiae and E. coli respectively. The S. 
cerevisiae culture expressing PaDa I – UPO had the expected peroxidase activity against 
ABTS and peroxygenase activity against NBD, but no distinct protein band was observed 
at the expected molecular weight of 51.1 kDa vis à vis the empty vector control. 
Subsequent expressions at different temperatures (25 and 20 ˚C), different induction 
points (two, two and a half, and three doubling times), and six Kozak sequences (based 
on either the vertebrate or native S. cerevisiae Kozak sequence) yielded an increase of 
total activity to approximately 1.5 U/mL, with the highest activity of any single culture 
being 1.63 ± 0.058 U/mL or 47.9% of the reported total activity (3.4 U/mL) achieved in 
the original paper.19   
 Precipitation of the PaDa I-UPO culture supernatant with 30% ammonium sulfate 
appeared to remove many of the contaminating proteins without reducing total activity, 
however fractional precipitation up to 60% ammonium sulfate concentrated but did not 
further purify PaDa I – UPO, with the PaDa I – UPO and empty vector control fractions 
containing the same visible protein bands by SDS-PAGE. Ion exchange chromatography 
resulted in no further purification, as PaDa I – UPO was not retained by the cation 
exchange column. Though it was not purified further, PaDa I – UPO was demonstrated to 
have activity against terpenes by GC/MS analysis, converting limonene to limonene 
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epoxide and carveol (replicating the findings of Sebastian, et al)23 and Δ6-protoilludene 
to a probably oxygenated compound with a molecular weight of 220 daltons. 
 In order to increase production of PaDa I – UPO and obtain a distinct enzyme 
band by SDS – PAGE, a logical next step will be to express it in the methylotrophic yeast 
Pichia pastoris. PaDa I – UPO has been expressed in P. pastoris in the literature, and 
while this did not increase PaDa I – UPO production in flask fermentation it did result in 
a 27 fold increase over S. cerevisiae in fed batch fermentation.29 It is also possible that a 
distinct band for PaDa I – UPO is present even without increasing production, but this 
band is hidden by a contaminant protein band at the same molecular weight in both the 
empty vector control and the expression culture. As PaDa I – UPO is glycosylated 
(Molina – Espeja et al., 2014) its molecular weight might vary from the expected value of 
51.1 kDa, and thus it could be present in the 75 kDa band seen in expression cultures and 
empty vector controls. Mass spectrometry of this protein band would be able to ascertain 
whether it contains PaDa I – UPO. Ultimately PaDa I – UPO should be purified in order 
to certify that it alone is responsible for activity against Δ6-protoilludene or other 
terpenes, and to determine if it would be more active in purified form. As PaDa I – UPO 
has been purified using ion exchange chromatography19 this will continue to be pursued, 
with additional adjustments made to buffers and the type of column used so that the 
enzyme remains on the column. Once PaDa I – UPO is produced in sufficient quantity 
and purified, the final goal is to use it as a scaffold modifying enzyme in a biocatalytic 
cascade that can convert Δ6-protoilludene and possibly other terpenes to bioactive 
terpenoids. For this to be feasible, PaDa I – UPO should remain active over a relatively 
long period of time and convert a significant amount of Δ6-protoilludene to the modified 
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product in a repeatable manner, neither of which it currently does. It has been 
demonstrated that PaDa I – UPO remains active for a longer period of time when H2O2 is 
added slowly into the reaction,47 thus for future terpene modification reactions H2O2 
should be added slowly through a device such as a pump. 
As many terpenoids contain multiple oxygen atoms, possessing a toolbox of 
scaffold modifying enzymes with the ability to oxygenate different positions on a 
molecule is essential. As cytochrome P450s have proven difficult to express in active 
form, the flavin-binding enzymes FAD1, FAD2, GMC2, RED1, and Omp7a were 
investigated for potential use alongside E. coli Fre. While FAD1, GMC2, RED1, and Fre 
expressed strongly in E. coli, initial expressions were insoluble. Altering conditions such 
as inductant concentration, expression temperature, induction time, and expression time 
resulted in soluble expression of Fre and possible soluble expression of RED1. The next 
step will be to attempt purification of Fre and RED1 using affinity chromatography, 
likely with nickel ion resin. It is not uncommon for heterologous proteins to be in 
inclusion bodies when expressed in E. coli, and there remain a number of techniques that 
can be attempted in order to produce soluble FAD1 and GMC2. One avenue that should 
be attempted is adding a flavin source to the expression media, as this can aid in the 
expression of soluble flavoenzymes.60 Other methods which can be tried include 
molecular techniques to lower expression rate (i.e. weaker promoter or using a lower 
copy number plasmid), performing expressions with various other media types besides 
Luria-broth, and denaturing and refolding the insoluble protein in vitro through the 
addition and slow removal of a denaturant. Another step that should be taken would be to 
co-express Δ6-protoilludene synthase with FAD1, GMC2, and RED1 and observe 
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whether these enzymes are active in vivo against Δ6-protoilludene in spite of their 
insolubility in vitro, with activity being measured by GC/MS analysis of the culture 
headspace. Ultimately, while I was not able to complete a biosynthetic pathway to ∆6-
protoilludene derivatives or other sesquiterpenoids, there was some promise in PaDa I – 
UPO’s activity against ∆6-protoilludene. Potentially, this enzyme could be used in a 
biosynthetic cascade. In terms of the flavin-binding enzymes, while no scaffold 
modifying enzymes were shown to be active in vitro, first steps were taken toward their 
heterologous expression and isolation.  
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Supplemental Materials 
PaDa I – UPO assay against valencene 
In addition to assaying PaDa I – UPO against limonene and Δ6-protoilludene, 
PaDa I – UPO was also assayed against the sesquiterpene valencene. The reaction set up 
and GC/MS trial were identical to that described for limonene in the materials and 
methods section of Chapter 1.  
 
 
 
 
 
Yeast transformation protocol 
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Figure S1. A) Empty vector control + valencene, B) PaDa I – UPO + valencene.    
Both chromatograms appeared to show multiple peaks, but all peaks in both 
chromatograms were identified as valencene by NIST. It would thus appear that 
PaDa I – UPO lacks activity against valencene. 
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The protocol used to transform pESC-ura plasmids into S. cerevisiae (Chapter 2) is 
described here. Note this protocol was developed by Dr. Sarah Perdue of the Claudia 
Schmidt-Dannert lab. 
1. Scrape several fresh yeast colonies (approximately 25 μL of inoculum) from a 
plate into 1 mL of sterile H2O. 
2. Pellet the cells for 5 seconds 
3. Resuspend the cells in 1 mL 100 mM LiAc and incubate at room temperature for 
5 minutes. For each transformation you are performing, boil 10 μL of 10 mg/mL 
salmon sperm carrier DNA for 5 minutes.  
4. For each transformation, remove 250 μL of the resuspended yeast cells. Pellet this 
aliquot for five seconds, and remove supernatant.  
5. Add the following sterile components to each cell pellet being transformed: 
 240 μL of 50% PEG 3350 
 36 μL of 1.0 M LiAc 
 10 μL of 10 mg/mL salmon sperm carrier DNA (boiled) 
 64 μL of water 
6. Add DNA. For an intact plasmid, add 2.5 μL of a standard vector miniprep. 
7. Vortex reaction mixture for 1 minute to resuspend the pellet   
8. Incubate at 42 ˚C for 20 minutes.  
9. Pellet cells for 10 seconds at top speed. Discard the supernatant.  
10. Resuspend pellet in 400 μL H2O. 
11. Plate 5 – 200 μL of the mixture from step 10 on selective media. Incubate at 30 ˚C 
for 2-3 days.  
 
